<DOC>
	<DOCNO>NCT02455726</DOCNO>
	<brief_summary>Magnesium exerts analgesic effect several animal pain model patient affect acute postoperative pain chronic pain neuropathic origin . There evidence magnesium modulate pain patient peripheral arterial occlusive disease ( PAOD ) . We describe protocol single-center randomize double-blind clinical trial aim assess efficacy oral magnesium supplementation control severe pain patient advance PAOD .</brief_summary>
	<brief_title>Magnesium Oral Supplementation Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease</brief_title>
	<detailed_description>- Adult patient admit Acute Pain Service intractable pain eligible affected PAOD stage III IV Lèriche-Fontaine classification , opioid-naïve . - Patients enrolled randomize control group , treat standard therapy , consist oral administration oxycodone 5 mg pregabalin 25 mg per day plus placebo ( fructose 10 g ) twice day two week , experimental group , treat magnesium oxide 300 mg twice day . - Randomization computer-generated , allocation concealment obtain use opaque , sequentially number sealed envelope . Trials participant , care provider , data collector , outcome assessor data analyst blind treatment allocation . - Patients evaluate day hospital admission ( day 0 ) day 2 , 4 , 6 , 8 , 12 , 14 follow information collect : daily oxycodone dose receive ; patient 's perceived average maximum pain use Numerical Rating Scale ( NRS : 0=no pain 10=worst possible pain ) ; pain relief use Pain Relief Scale ( PRS : 0 % pain relief 100 % complete pain relief ) ; characteristic pain , use Neuropathic Pain Scale ( NPS : 10 item ) ; impact pain patient 's daily activity , use Brief Pain Inventory ( BPI ; 9 item ) . - A sample size calculation perform primary outcome show 150 patient ( 75 per group ) need achieve 90 % power detect minimum reduction 30 % oxycodone dosage experimental group , allow drop-out rate around 20 % . - Ethical approval study protocol obtain Comitato Etico Provinciale di Brescia , Brescia , Italy .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>adult patient ( 18 year ) PAOD stag III IV accord LèricheFontaine classification treatment opioids time recruitment renal failure ( serum creatinine ≥ 2.0 mg/dl ) ; congestive heart failure ( New York Heart Association , NYHA &gt; 3 ) ; treatment digoxin and/or calcium channel blocker ; preexist neuromuscular disease ; chronic diarrhea ; acute limb ischemia successfully treat interventional angiography , Fogarty embolectomy and/or surgical revascularization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Magnesium Oxide</keyword>
	<keyword>Pain</keyword>
</DOC>